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Introduction
Atrial fibrillation (AF) is the most common arrhythmia, 
and increases the risk of stroke and systemic embolism [1]. 
Thromboembolic event rates vary from 2 to 18 % yearly, 
depending on clinical and/or echocardiographic risk fac-
tors [2–5]. In addition to transthoracic echocardiography, 
transesophageal echocardiography can be a potentially use-
ful diagnostic imaging modality. It can diagnose left atrial 
thrombi with accuracy, as well as abnormal flow in the left 
atrium due to stasis of blood flow [6, 7]. This so-called 
low flow state is characterized by the presence of left atrial 
spontaneous echo contrast (SEC), and is accompanied by 
low left atrial appendage peak filling and emptying flow 
velocities [8–10]. SEC is defined as an echodense whirling 
pattern that may be visible on transesophageal echocardio-
gram [11, 12]. SEC is considered to be closely related to 
thromboembolic events [13, 14]. Hematocrit, fibrinogen 
concentration, brain natriuretic peptide (BNP), and high-
sensitivity C-reactive protein (hs-CRP) have been closely 
related to SEC [15, 16].
Oral anticoagulation therapy is the standard of care for 
outpatient prevention of stroke and systemic embolism in 
patients with AF. Warfarin substantially decreases the risk 
of stroke in patients with nonvalvular AF, but it increases 
the risk of major bleeding [2]. The introduction of novel 
oral anticoagulants (NOACs) provides new options for 
periprocedural anticoagulation. A direct thrombin inhibi-
tor (DTI), dabigatran was approved as an alternative to 
warfarin for prevention of stroke and systemic embolism in 
Abstract The presence of spontaneous echo contrast 
(SEC) in the left atrium has been reported to be an inde-
pendent predictor of thromboembolic risk in patients with 
atrial fibrillation (AF). Dabigatran was associated with 
lower rates of stroke and systemic embolism as compared 
with warfarin when administered at a higher dose. Between 
July 2011 and October 2015, nonvalvular AF patients 
treated with warfarin or dabigatran who had transesopha-
geal echocardiography prior to ablation therapy for AF 
were enrolled. The intensity of SEC was classified into 
four grades, from 0 to 3. Univariate and multivariate analy-
sis was performed to analyze factors associated with SEC. 
Sixty-five patients were on dabigatran and 65 were on 
warfarin, with the prothrombin time in therapeutic range. 
There were no significant differences in the age, CHADS2 
score, left atrial dimension, and left atrial appendage flow 
between the two groups. However, there were more grade 2 
or higher patients with left atrial SEC in the warfarin group 
(n = 20) than in the dabigatran group (n = 2) (p < 0.001). 
When multivariate regression analysis was performed, 
grade 2 or higher left atrial SEC was independently asso-
ciated with no dabigatran usage in addition to high brain 
natriuretic peptide level and high incidence of diabetes 
mellitus or persistent AF. Thus, dabigatran exhibited low 
intensity of left atrial SEC in nonvalvular AF patients as 
compared with warfarin.
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patients with AF [17]. The intensity of left atrial SEC could 
be affected by the medication used. However, there are no 
SEC reports that compare warfarin with dabigatran. The 
purpose of this study was to examine the difference in the 
intensity of left atrial SEC between AF patients treated with 
warfarin and those with dabigatran.
Materials and methods
Study patients
This retrospective study included 130 patients who had 
been admitted for ablation therapy in Yao Municipal Hospi-
tal and Kansai Rosai Hospital between July 2011 and Octo-
ber 2015. All of the patients were nonvalvular AF [mean 
age: 65 ± 9 years; men: 90 (69 %); paroxysmal AF: 56 
(43 %)]. The patients were treated with warfarin or dabi-
gatran and underwent transesophageal echocardiography 
prior to ablation therapy for AF. Oral anticoagulants (war-
farin and dabigatran) were interrupted just before ablation 
theraphy.
Study design
We essentially adopted the dose of dabigatran similar as the 
arm of a higher dose in RE-LY study (150 mg twice daily). 
However, the dose of dabigatran was reduced according to 
renal dysfunction or concomitant use of other drugs. For 
the patients with creatinine clearance 30–50 mL/min or 
concomitant use of P-glycoprotein inhibitors, we reduced 
dabigatran dose 110 mg twice daily.
Patients with significant mitral valve disease or a val-
vular prosthesis were excluded from the study. AF was 
documented from a 12-lead electrocardiogram or Holter 
electrogram before the transesophageal echocardiogra-
phy examination. Clinical parameters, such as sex, age, 
AF type, history of hypertension, heart failure or throm-
boembolism, and blood tests were analyzed and entered 
into a regression analysis. A written informed consent 
was obtained for all patients. The entire investigation con-
formed to the principles outlined in the Declaration of Hel-
sinki and this study was approved by ethical committee of 
our hospitals.
Echocardiographic measurements
Transthoracic and transesophageal echocardiography were 
performed with a TOSHIBA echocardiogram (ARTIDA™, 
Toshiba, Tokyo, Japan). Transthoracic echocardiogra-
phy was performed with a broadband 3-MHz phased-
array transducer connected to an ultrasound system and 
transesophageal echocardiography was performed with 
a 5-MHz multiplane transducer. Prior to transesopha-
geal echocardiography, all patients fasted for at least 4 h. 
Premedication was not given, but a local anesthetic was 
sprayed into the hypopharynx. Transesophageal echocardi-
ography was conducted to evaluate the presence or absence 
of left atrial thrombus, presence or absence of left atrial 
SEC, and left atrial appendage emptying peak flow veloc-
ity, as described previously [8, 10, 18, 19]. All the patients 
underwent transthoracic and transesophageal echocardiog-
raphy after at least 3 weeks on warfarin, with a target pro-
thrombin time-international normalized ratio (PT-INR), or 
after at least 3 weeks on dabigatran 8 ± 1 h after the last 
dosage. In the guideline of the Japanese Circulation Soci-
ety, the suitable level of PT-INR during warfarin therapy 
for nonvalvular AF is 2.0–3.0 in patients aged <70 years 
but is 1.6–2.6 in patients aged ≥70 years to avoid bleeding 
complications.
The intensity of SEC was classified into four grades, 
from 0 to 3. Grade 0 was no SEC, and grade 1 was mild, 
indicating minimal echogenicity in the left atrial append-
age. Grade 2 was moderate, and demonstrated a dense 
swirling pattern in the main cavity. Grade 3 was severe, and 
demonstrated intense echodensity, with very slow swirl-
ing patterns in the main cavity (Fig. 1). For the evaluation 
of SEC, two experienced observers reviewed the digital 
images during an offline analysis without current knowl-
edge of the patient and other imaging results.
Statistical analysis
All statistical analyses were performed using StatFlex for 
Windows Version 6 (Artech Co. Ltd., Osaka, Japan). Quan-
titative variables were expressed as mean ± standard devia-
tion. For comparison of measurements between warfarin 
and dabigatran, Student’s t test was used for continuous 
variables, and the χ2 test for categorical variables. Multi-
variate regression analysis was performed to investigate the 
independent factors for the presence of moderate/severe 
left atrial SEC. Values were considered significant when 
the p value was <0.05.
Results
Patient backgrounds
Of 130 patients, 65 (50 %) were on warfarin and 65 (50 %) 
were on dabigatran. In patients treated with dabigatran, the 
reduced dose (110 mg twice daily) was prescribed in 29 
patients. Previous heart failure was present in 27 patients 
(21 %), hypertension in 75 (58 %), diabetes mellitus in 14 
(11 %), and previous cerebral infarction in 9 (7 %). The 
mean CHADS2 score was 1.1 ± 0.9. Patient backgrounds 
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comparing warfarin and dabigatran groups are presented 
in Table 1. Age, sex, history of heart failure, hypertension, 
diabetes mellitus and previous stroke, and CHADS2 score 
were not different between the two groups. There were 
lower numbers of people of paroxysmal AF in warfarin 
group in comparison with the dabigatran group.
Comparison between warfarin and dabigatran groups
Laboratory data for warfarin and dabigatran groups are 
presented in Table 2. Activated partial thromboplastin time 
(APTT), hematocrit, creatinine clearance, CRP, and BNP 
were not significantly different between the two groups, 
but PT-INR was higher in the warfarin group (p < 0.001). 
Table 2 also displays the characteristics of the transthoracic 
and transesophageal echocardiographic parameters. There 
were no significant differences in left ventricular end-dias-
tolic dimension, left ventricular end-systolic dimension, 
left ventricular ejection fraction, left atrial dimension, and 
left atrial appendage flow between the two groups. How-
ever, there were more grade 2 or higher patients with left 
atrial SEC in the warfarin group compared to the dabi-
gatran group [20/65 (31 %) vs. 2/65 (3 %); p < 0.001]. In 
the two dabigatran-treated patients showing SEC grade 2 or 
higher, one was treated with a high dose (300 mg/day) and 
the other with a low dose (220 mg/day). Left atrial throm-
bus was detected only in five patients treated with warfarin 
and their mean PT-INR level was 2.1.
Fig. 1  The intensity of left atrial spontaneous echo contrast (SEC) was classified into four grades, from 0 to 3. Grade 0 was no SEC (a), grade 1 
mild (b), grade 2 moderate (c) and grade 3 severe (d)
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Univariate and multivariate analysis for SEC grade
There were significant differences between the patients 
with SEC grade 0/1 (n = 108) and grade 2/3 (n = 22) in the 
incidence of previous heart failure, diabetes mellitus, cer-
ebral infarction and paroxysmal AF, and in CHADS2 score, 
PT-INR, BNP, left atrial dimension and medication with 
warfarin or dabigatran (Table 3). When multivariate regres-
sion analysis was performed using these significant factors, 
the patients with SEC grade 2/3 were independently associ-
ated with no dabigatran usage [odds ratio: 0.019 (95 % CI 
0.001–0.963, p = 0.047)]; in addition to high levels of BNP 
[odds ratio: 1.008 (95 % CI 1.002–1.015, p = 0.010)]; and 
the incidence of diabetes mellitus [odds ratio: 11.30 (95 % 
CI 1.218–576.6, p = 0.018)]; or persistent AF [odds ratio: 
0.023 (95 % CI 0.001–0.561, p = 0.020)].
Discussion
Our study showed that there were more grade 2 or higher 
patients with left atrial SEC in the warfarin group than in 
the dabigatran group. However, there were no significant 
differences in age, CHADS2 score, left atrial dimension, 
and left atrial appendage flow between the warfarin and 
dabigatran groups. A previous study reported that hema-
tocrit and CRP are independent predictors of SEC in AF 
patients [20]. In this study, however, these factors were not 
significantly different between the two groups.
Recently, transesophageal echocardiography has been 
routinely performed before AF ablation therapy or cardio-
version, because the presence or absence of thrombus in the 
atrium is critical for the ablation or cardioversion proce-
dure. Transesophageal echocardiography is the most sensi-
tive and specific tool to detect thrombus in the left atrium 
[7, 8, 21]. Transesophageal echocardiography can stratify 
high-risk patients with nonvalvular AF by identifying left 
atrial SEC. SEC is a positive predictor of stroke or systemic 
embolism [22]. Patients with thrombus or moderate/severe 
SEC in the left atrium must receive intensive anticoagula-
tion therapy to avoid thromboembolic events. However, the 
intensity of the effects of warfarin and dabigatran on the 
left atrial SEC may differ.
In recent years, the NOACs, such as dabigatran (DTI), 
and rivaroxaban, apixaban, and edoxaban (direct Factor Xa 
inhibitors), have been approved for primary and secondary 
prevention of stroke in patients with nonvalvular AF. Com-
pared with traditional agents such as warfarin, the NOACs 
offer benefits in terms of efficacy, safety, and conveni-
ence. Dabigatran 150 mg twice daily was the only NOAC 
with a decreased incidence of ischemic stroke, and with-
out increased risk of bleeding, as compared with warfarin. 
In RE-LY sub-analysis, there were no treatment-by-region 
interaction for either dose of dabigatran on stroke, ischemic 
stroke and death between in Asians and in non-Asians [23]. 
Moreover, in Asian patients with nonvalvular AF, the mag-
nitude effect for each outcome of dabigatran 220 mg daily 
Table 1  Patient backgrounds comparing warfarin and dabigatran 
groups
Italics indicate metastatic SNs
AF atrial fibrillation
Warfarin Dabigatran p value
(n = 65) (n = 65)
Age (years) 67 ± 8 65 ± 10 0.113
Men 46 (71 %) 44 (68 %) 0.424
Previous heart failure 15 (23 %) 12 (18 %) 0.332
Hypertension 35 (54 %) 40 (62 %) 0.238
Diabetes mellitus 5 (8 %) 9 (14 %) 0.197
Cerebral infarction 7 (11 %) 2 (3 %) 0.083
CHADS2 score 1.2 ± 1.0 1.1 ± 0.9 0.465
AF
 Paroxysmal 21 (32 %) 35 (54 %) 0.011
 Persistent 44 (68 %) 30 (46 %)
Table 2  Laboratory and echocardiographic data in warfarin and dab-
igatran groups
Italics indicate metastatic SNs
PT-INR prothrombin time-international normalized ratio, APTT acti-
vated partial thromboplastin time, Ccr creatinine clearance, CRP 
C-reactive protein, BNP brain natriuretic peptide, LVDd left ventricu-
lar end-diastolic dimension, LVDs left ventricular end-systolic dimen-
sion, LVEF left ventricular ejection fraction, LAD left atrial dimen-
sion, LAA left atrial appendage, SEC spontaneous echo contrast




 PT-INR 2.2 ± 0.5 1.2 ± 0.3 <0.001
 APTT (s) 43 ± 8 44 ± 12 0.401
 Hematocrit (%) 41 ± 4 41 ± 5 0.474
 Ccr (mL/min) 67 ± 24 71 ± 21 0.265
 CRP (mg/dL) 0.14 ± 0.51 0.13 ± 0.37 0.902
 BNP (pg/mL) 144 ± 143 116 ± 113 0.226
Echocardiographic data
 LVDd (mm) 47 ± 5 48 ± 5 0.418
 LVDs (mm) 31 ± 6 30 ± 4 0.918
 LVEF (%) 65 ± 8 65 ± 8 0.910
 LAD (mm) 42 ± 8 41 ± 7 0.953
 LAA flow (cm/s) 39 ± 20 42 ± 19 0.394




 Grade 0 or 1 (0/1) 45 (32/13) 63 (44/19) <0.001
 Grade 2 or 3 (2/3) 20 (14/6) 2 (1/1)
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was comparable with that of 300 mg dose [24]. In our study, 
45 % of dabigatran patients were prescribed 220 mg daily. 
The main reason of this low dose dabigatran use was due 
to renal dysfunction or concomitant use of P-glycoprotein 
inhibitors. Even in these patients, dabigatran 220 mg daily 
use may be more effective to reduce SEC than warfarin [25].
Dabigatran is a univalent DTI that exerts anticoagu-
lant effects by binding to the active site of thrombin. In a 
blood clot, the heparin–antithrombin complex cannot bind 
fibrin-bound thrombin. In contrast, given their mechanism 
of action, DTIs can bind to and inhibit the activity of not 
only soluble thrombin but also thrombin bound to fibrin. 
Since they reduce the thrombin-mediated activation of 
platelets, DTIs also have an antiplatelet effect. DTIs do 
not bind to plasma proteins, and therefore, should produce 
a more predictable response than unfractionated heparin. 
They should also be more effective than low-molecular-
weight heparin because DTIs can inhibit fibrin-bound 
thrombin [26]. Dabigatran enhances the susceptibility 
of plasma clots to tissue-plasminogen activator-induced 
lysis by reducing thrombin-activatable fibrinolysis inhibi-
tor activation, and by altering the clot structure at clini-
cally relevant concentrations [27]. Dabigatran can dis-
solve a clot by such a mechanism. In fact, the potential 
thrombolytic effect of dabigatran has been previously 
reported [28–30].
Study limitations
This study is associated with some limitations. First, our 
study population comprised relatively small number of 
patients recruited from two centers. Therefore, large-number 
data collected in a multicenter are needed. Second, our study 
was not performed in a randomized fashion, although the 
major factors that can affect our primary results were not dif-
ferent between warfarin and dabigatran groups. Dabigatran, 
a DTI, has a potent antithrombin effect, and in high doses 
decreased ischemic stroke without increased risk of bleed-
ing in patients with nonvalvular AF, compared with warfarin 
[16]. Therefore, reduced SEC in the left atrium found in the 
dabigatran group may be direct evidence for its clinical effect. 
The finding that moderate or severe left atrial SEC was inde-
pendently associated with no dabigatran usage confirms this. 
Finally, in the Japanese guidelines, recommended target PT-
INR levels were relatively low compared to other countries 
in patients aged ≥70 years. This proportion might be affected 
in our results. A large-scale, randomized, prospective study is 
needed to confirm the results shown in this study.
Table 3  Factors affecting SEC 
grade
Italics indicate metastatic SNs
SEC spontaneous echo contrast, AF atrial fibrillation, PT-INR prothrombin time-international normalized 
ratio, APTT activated partial thromboplastin time, Ccr creatinine clearance, CRP C-reactive protein, BNP 
brain natriuretic peptide, LVDd left ventricular end-diastolic dimension, LVDs left ventricular end-systolic 
dimension, LVEF left ventricular ejection fraction, LAD left atrial dimension
SEC grade Univariate Multivariate
0/1 (n = 108) 2/3 (n = 22) p value p value Odds ratio (95 % CI)
Age (years) 65 ± 9 69 ± 7 0.117 – –
Men 75 (69 %) 15 (68 %) 0.554 – –
Previous heart failure 19 (18 %) 8 (36 %) 0.045 0.345 2.599 (0.357–18.90)
Hypertension 60 (56 %) 15 (68 %) 0.196 – –
Diabetes mellitus 8 (7 %) 6 (27 %) 0.009 0.018 11.30 (1.218–576.6)
Cerebral infarction 5 (5 %) 4 (18 %) 0.034 0.454 2.900 (0.178–47.26)
Paroxysmal AF 55 (51 %) 1 (5 %) <0.001 0.020 0.023 (0.001–0.561)
CHADS2 score 1.0 ± 0.9 1.9 ± 1.0 <0.001 0.240 1.921 (0.646–5.715)
PT-INR 1.6 ± 0.6 2.2 ± 0.6 <0.001 0.058 6.175 (0.938–40.64)
APTT (sec) 44 ± 11 44 ± 7 0.994 – –
Hematocrit (%) 41 ± 5 42 ± 5 0.254 – –
Ccr (mL/min) 70 ± 23 64 ± 21 0.297 – –
CRP (mg/dL) 0.11 ± 0.30 0.26 ± 0.88 0.177 – –
BNP (pg/mL) 111 ± 109 223 ± 175 <0.001 0.010 1.008 (1.002–1.015)
LVDd (mm) 47 ± 5 48 ± 5 0.757 – –
LVDs (mm) 30 ± 5 31 ± 5 0.388 – –
LVEF (%) 65 ± 8 63 ± 10 0.218 – –
LAD (mm) 41 ± 7 44 ± 11 0.047 0.647 1.018 (0.940–1.103)
Dabigatran usage 63 (58 %) 2 (9 %) <0.001 0.047 0.019 (0.001–0.963)
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Conclusion
In patients with nonvalvular AF, dabigatran administration 
is probably more effective for reducing left atrial SEC as 
compared with warfarin.
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